CDX 6114

Drug Profile

CDX 6114

Alternative Names: CDX-6114; Phenylketonuria therapeutic enzyme - Codexis

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Codexis
  • Developer Codexis; Nestle Health Science
  • Class Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Phenylketonuria

Most Recent Events

  • 09 Jul 2018 Phase-I clinical trials in Phenylketonuria (In volunteers) in Australia (PO) (NCT03577886)
  • 09 Jul 2018 Codexis plans a phase I trial for CDX 6114 in Phenylketonuria (In volunteers) in July 2018 (NCT03577886)
  • 31 Dec 2017 Codexis has patent protection for CodeEvolver® technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top